The aim of proposed research work was to develop a bioadhesive sustained release matrix tablets of
zolmitriptan for treatment of migrane. Compression coating technology was used for preparing the tablets that released the
drug unidirectionally. Drug loaded core tablets were prepared with mucoadhesive and sustained release polymers like
Noveon AA1 Polycarbophil and hydroxypropyl methylcellulose (HPMC K4M) while unloaded coat tablets, that covered
the three surfaces of the core tablet, were prepared using ethyl cellulose and Compritol ATO 888. A two factor, three
level, face centred, central composite design (CCD) was used to optimize amount of Noveon AA1 and amount of HPMC
so as to get required mucoadhesion and rate of drug release. Higher levels of HPMC K4M in the experimental design
batches exhibited higher in vitro drug release in the initial hour while the NoveonAA1 levels could be related to increase
in mucoadhesive strength. Overlay plot comprising a region that satisfied the constraints for all the selected attributes was
generated. Formulation containing 10% w/w of Noveon AA1 and 10% w/w of HPMC K4M was found to be optimum.
Checkpoint batches were also prepared to validate the evolved mathematical models. Korsmeyer-Peppas release kinetic
model best fitted the optimized batch release profile which showed anomalous diffusion mechanism. The In Vitro drug
release could be correlated with the Ex vivo drug permeation. It can be concluded that buccal route can be one of the
alternatives available for administration of zolmitriptan.
Keywords: Unidirectional buccal delivery, zolmitriptan, design of experiment, mucoadhesive delivery, compression coating, allergens, URBT, ANOVA, Mucoadhesion, interpenetration, Korsmeyer-Peppas model, receptor compartment, mucosa, mucoadhesion, saliva
Rights & PermissionsPrintExport